Marinomed Signs Drug Discovery Collaboration with BIOALVO
Marinomed Biotechnologie GmbH announced the signing of a deal with the Portuguese company BIOALVO under which the two companies will collaborate to find drug candidates screened from BIOALVO’s PharmaBUG marine extract library. Financial terms were not disclosed.
Under the terms of the deal BIOALVO will grant Marinomed access to BIOALVO’s PharmaBUG natural marine extracts. Marinomed will then have exclusive rights to use its own screening platform to identify those with therapeutic potential for indications in the areas of immunology and infectious diseases.
Dr Andreas Grassauer, CEO and co-founder of Marinomed, commented: “We are delighted to have signed this collaboration with BIOALVO. The rich source of natural marine extracts from PharmaBUG offers us a unique resource to screen and hopefully generate new natural leads for development in our core therapeutic indications.”
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.